RUBICON Rubicon Research Q4 FY26 results (Jan–Mar 2026) and concall
Rubicon Research delivered strong Q4 FY26 results, with revenue growing 44% YoY to ₹5,140 million and EBITDA up 67% YoY to ₹1,210 million. Full-year PAT increased 84% to ₹2,467 million. The company highlighted robust R&D productivity and a strong pipeline of 24 products under FDA review. Gross margins saw a slight dip due to increased outsourced manufacturing, a temporary measure, and finance costs rose sequentially due to recent M&A and factoring activities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 43.6%, net profit up 113.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 296 | 313 | 358 | 352 | 412 +39% | 476 +52% | 514 +44% |
| EBITDA | 62 | 70 | 72 | 79 | 94 +52% | 108 +54% | 119 +65% |
| Net profit | 34 | 38 | 36 | 43 | 54 +59% | 73 +92% | 77 +114% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
